Compounded topical finasteride products have been associated with serious potential risks, warns Food and Drug Administration (FDA) in a news release. Between 2019 and 2024, 32 reports were submitted to the FDA Adverse Event Reporting System regarding patients experiencing symptoms such as erectile dysfunction, anxiety, suicidal ideation, and brain fog associated with using compounded versions of this medication. FDA has approved two oral finasteride products for different medical conditions: Proscar® and Propecia®. No topical products containing finasteride alone or in combination with other ingredients are FDA approved. FDA recommends that health care providers inform patients about the potential risks associated with using compounded topical finasteride.